BIRC5 and cancer: The differential expression of Survivin in OSCC and normal cells suggests that Survivin serves as a potential cancer therapy target; will facilitate tailoring therapeutic strategies; and can be chosen as a community noninvasive screening test (CNST) in habitual tobacco chewers, as well as for the prognosis of OSCC patients during management as buccal cell samples are easy to collect and patient-compliant.